From "Balancing the Benefits of Primary Angioplasty against the Benefits of Thrombolytic Therapy for Acute Myocardial Infarction: The Importance of Timing" Effective Clinical Practice, September/October 2001. 4:214-220.
Figure 2. Absolute risk reduction in 30-day mortality rate, with PTCA as a function of PTCA-related delay. The size of the circle reflects the study sample size. Values above zero represent benefit, and values below zero represent harm. Line = weighted regression.>